ANVS
Annovis Bio, Inc.Company Information
- Company Name
- Annovis Bio, Inc.
- CIK
- CIK0001477845
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ANVS: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ANVS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-20
- Last sale
- —
- Shares purchased (TTM)
- 1,982,515
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 9,392,717
- Shares outstanding
- 37,518,778
- Ownership
- 25.03%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -24.86%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 14 | 20 | 15 | 17 | 22 | 11 | 13 | 4 | 3 | 6 | 6 | ||||||
| Assets Current | - | - | - | - | - | - | - | - | - | 8 | 10 | 10 | ||||||
| Assets | 22 | 16 | 21 | 17 | 21 | 27 | 14 | 14 | 5 | 8 | 10 | 10 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 5 | 3 | 2 | 1 | 1 | 2 | 4 | 3 | 4 | 1 | 2 | ||||||
| Liabilities Current | 6 | 13 | 4 | 4 | 3 | 3 | 4 | 5 | 4 | 5 | 4 | 4 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | - | 0 | 1 | 6 | 14 | - | ||||||
| Liabilities | 26 | 13 | 4 | 4 | 3 | 3 | 5 | 7 | 7 | 11 | 18 | 4 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 192 | 184 | 181 | 167 | 165 | 164 | 144 | 136 | 115 | 108 | 103 | 95 | ||||||
| Retained Earnings Accumulated Deficit | -196 | -181 | -164 | -154 | -147 | -140 | -135 | -129 | -116 | -111 | -110 | -88 | ||||||
| Stockholders Equity | -4 | 3 | 17 | 13 | 18 | 24 | 9 | 7 | -2 | -3 | -8 | 7 | ||||||
| Liabilities And Stockholders Equity | 22 | 16 | 21 | 17 | 21 | 27 | 14 | 14 | 5 | 8 | 10 | 10 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | 70 | ||||||
| Common Stock Shares Issued | 43 | 29 | 27 | 20 | 19 | 19 | 14 | 13 | 12 | 11 | 11 | 9 | ||||||
| Shares Outstanding | 43 | 29 | 27 | 20 | 19 | 19 | 14 | 13 | 12 | 11 | 11 | 9 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAnnovis Bio, Inc. (ANVS) — SEC Financial Statements & Analysis
Annovis Bio, Inc. (ANVS) is a pharmaceutical preparations company, incorporated in DE. Annovis Bio, Inc. trades on NYSE as: ANVS. Annovis Bio, Inc. (ANVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Annovis Bio, Inc. carries a market cap of $69.78M, a P/E ratio of -1.41x, a P/B ratio of -16.40x, an enterprise value of $51.06M, and an EV/EBITDA multiple of -1.03x. On profitability, it posts a Return on Equity (ROE) of -703.68%, a Return on Assets (ROA) of -284.97%, and a Return on Invested Capital (ROIC) of -2915.54%. Per share, it reports EPS of $-1.32, diluted EPS of $-1.32, free cash flow per share of $-1.16, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 63.66% year-over-year and EPS growth of -15.00% year-over-year. On the balance sheet, it maintains a current ratio of 1.60x, a quick ratio of 1.60x, working capital of $2.94M, a debt-to-equity ratio of -6.18x, a debt ratio of 1.43, an interest coverage ratio of -968.81x, free cash flow of $-43.34M (TTM), and net debt of $-18.73M. Figures sourced from SEC EDGAR.
- Market Cap
- $69.78M
- P/E TTM
- -1.41x
- EPS TTM
- $-1.32
- P/B TTM
- -16.40x
- ROE TTM
- -703.68%
- ROA TTM
- -284.97%
- Debt To Equity
- -6.18x
- Free Cash Flow TTM
- $-43.34M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Annovis Bio, Inc. in?
Annovis Bio, Inc. (ANVS) operates in the Pharmaceutical Preparations industry.
What exchange does ANVS trade on?
Annovis Bio, Inc. (ANVS) trades on the NYSE.
Where is Annovis Bio, Inc. incorporated?
Annovis Bio, Inc. is incorporated in DE.
When was Annovis Bio, Inc. (ANVS)'s most recent SEC filing?
Annovis Bio, Inc. (ANVS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is ANVS's market cap?
Annovis Bio, Inc. (ANVS) has a market capitalization of $69.78M as of 2026-06-30.
What is ANVS's EPS (earnings per share)?
Annovis Bio, Inc. (ANVS)'s trailing twelve month EPS is $-1.32 as of 2026-06-30.
What is ANVS's ROE (return on equity)?
Annovis Bio, Inc. (ANVS)'s trailing twelve month Return on Equity (ROE) is -703.68% as of 2026-06-30.
What is ANVS's ROA (return on assets)?
Annovis Bio, Inc. (ANVS)'s trailing twelve month Return on Assets (ROA) is -284.97% as of 2024-03-31.
What is ANVS's ROIC (return on invested capital)?
Annovis Bio, Inc. (ANVS)'s trailing twelve month Return on Invested Capital (ROIC) is -2915.54% as of 2023-09-30.
What is ANVS's EV/EBITDA?
Annovis Bio, Inc. (ANVS)'s trailing twelve month EV/EBITDA is -1.03x as of 2026-06-30.